Publication of Large-Scale Clinical Study Results for Nematode-Based Cancer Screening Method “N-NOSE”Publication of Large-Scale Clinical Study Results

2024.07.24

HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)), has conducted a collaborative clinical study with the National Cancer Center and published the results of a large-scale clinical trial verifying the effectiveness of the innovative cancer screening test “N-NOSE” using nematodes as an original research paper.

In this clinical study, in addition to the 15 types of cancer previously reported to react to “N-NOSE”, it was newly revealed that nematodes also respond to gingival cancer, tongue cancer, parotid gland cancer, thyroid cancer, mediastinal tumors, malignant pleural mesothelioma, thymic cancer, peritoneal cancer, testicular cancer, ureteral cancer, malignant lymphoma, and malignant melanoma.

■Research Summary
・Period: May 2017 to March 2021
・Participants: Urine samples were collected from 1,664 newly diagnosed cancer patients at the Cancer Center (951 males, 713 females)
・Method: “N-NOSE” screening was conducted

■Summary of Study Results
1.The overall sensitivity of cancer detection ranged from 60-90%
2.High sensitivity was demonstrated for lung cancer, breast cancer, stomach cancer, colorectal cancer, cervical cancer, and prostate cancer, which are common worldwide
3.Detection of over 20 types of cancer
4.High sensitivity was shown even for early-stage cancers

These results indicate that “N-NOSE” has a high potential to detect small, early-stage cancers even without noticeable symptoms.

■Details of the Paper
・Title: A Non-Invasive Screening Method Using Caenorhabditis elegans for Early Detection of Multiple Cancer Types: A prospective clinical study
・Authors: Hideyuki Hatakeyama, Masayo Morishita, Aya Hasan Alshammari, Umbhorn Ungkulpasvich, Junichi Yamaguchi, Takaaki Hirotsu, Eric di Luccio
・Journal: Biochemistry and Biophysics Reports, 39:101778, 2024 (peer-reviewed)

In Japan, over 600,000 people have already undergone the “N-NOSE” test, demonstrating its practicality and effectiveness not only through clinical studies but also in real-world applications. Our company will continue to strive to improve the accuracy of “N-NOSE” daily, contributing to the early detection of cancer worldwide.

Download PDF